Skip to main content
OpenTrials
Completed

NCT Number: NCT02865863

A Study to Evaluate the Effect of a Study Product on Quality of Life and Mood

A phase II randomized, placebo controlled study evaluating the efficacy of Eurycomalongifoliawater extract (Physta®)+Multivitamin on quality of life and mood on 86 healthy adults over a 24 week supplementation period.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

25 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy subjects ≥ 25 and ≤ 65 years of age.
  • Body mass index (BMI) ≥ 18 and ≤30 kg/m2.
  • Subjects must be employed in a job/position that has some degree of responsibility such that they experience a mid-level of stress at work.
  • Subjects with a score of ≤ 18 in the Tension subscale and a score of ≤ 14 in the Fatigue subscale of the POMS Questionnaire.
  • Judged by the Investigator to be in general good health on the basis of medical history.
  • Females of child-bearing potential must agree to use appropriate birth control methods during the study.
  • Understands the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the study investigator
  • Understands the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the study investigator

Exclusion criteria

  • Subjects with any history of immune system disorder or auto-immune disorder including but not limited to the following:

*AIDS, HIV, Ankylosing Spondylitis, Chronic Fatigue Syndrome, CREST syndrome, Crohn's disease, Dermatomyositis, Fibromyalgia, Grave's disease, Hashimoto's Thyroiditis, Lupus, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, PolyarteritisNodosa, Primary Biliary Cirrhosis, Psoriasis, Reynaud's Syndrome, Rhematoid Arthritis, Sarcoidosis, Scleroderma, Sjogren's Syndrome, Temporal Arthritis, Ulcerative Colitis, and Vitiligo

  • Use of any immunosuppressive drugs in the last 12 months (including steroids or biologics)
  • Any significant GI condition that would severely interfere with the evaluation of the study product including but not limited to inflammatory bowel disease (Ulcerative Colitis or Chron's), history of frequent diarrhea, history of surgery for weight loss (including gastric bypass or lapband), history of perforation of the stomach or intestines, gastroparesis, clinically important lactose intolerance
  • Any active infection, or infection in the last month requiring antibiotics, antiviral medication, or hospitalization History or presence of cancer in the prior two years, except for non-melanoma skin cancer.
  • Subjects with a history of seizure
  • Recent history of (within 12 months) or strong potential for alcohol or substance abuse.
  • Participation in a clinical study with exposure to any non-registered drug product within 30 days prior.
  • Subject who are using herbal products containing androgenic/anxiolytic activity within 30 days (one month washout is allowed)
  • Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk. Including subjects who are Bed or wheelchair-bound
  • Untreated or unstable Hypothyroidism
  • Subjects with active eating disorder including anorexia nervosa, bulimia, and/or obsessive compulsive eating disorders
  • Central Neurological disorders including but not limited to Spinal cord injuries, multiple sclerosis, Parkinson's disease
  • Pregnant, lactating, planning to become pregnant or unwilling to use adequate contraception during the duration of the study.

Treatment and study plan

Eurycomalongifoliawater extract (Physta®)

Dietary Supplement

Placebo

Dietary Supplement

Multivitamin

Dietary Supplement

Primary outcomes

  1. The change in quality of life after 24 weeks of supplementation with study product, measured using the SF-12 Quality of Life Questionnaire

    Time frame: 24 Week

  2. The change in mood after 24 weeks of supplementation with study product, measured using the POMS Questionnaire

    Time frame: 24 week

Secondary outcomes

  1. The change in stress after 24 weeks of supplementation with study product, measured using the Multi-Modal Stress Questionnaire

    Time frame: 24 weeks

  2. The change in fasting AM Cortisol levels after 24 weeks of supplementation with study product.

    Time frame: 24 weeks

Other outcomes

  1. The change in CBC levels after 24 weeks of supplementation with study product

    Time frame: 24 weeks

  2. The change in CMP results after 24 weeks of supplementation with study product

    Time frame: 24 weeks

  3. The change in urinalysis results after 24 weeks of supplementation with study product

    Time frame: 24 weeks

  4. The number of adverse events reported after 24 weeks of supplementation with study product

    Time frame: 24 weeks

  5. The change in lipid panel results after 24 weeks of supplementation with study product

    Time frame: 24 weeks

  6. The change in total testosterone results after 24 weeks of supplementation with study product

    Time frame: 24 weeks

  7. The change in free testosterone results after 24 weeks of supplementation with study product

    Time frame: 24 weeks

Sponsors and collaborators

Lead sponsor

KGK Science Inc.

Industry

Collaborators

  • Biotropics Malaysia Berhad

Registry information

Official study title

Safety and Efficacy Profile of the Eurycomalongifoliawaterextract (Physta®)+Multivitamin Study Product

Important dates

Study start
2014
Primary completion
2015
First posted
Aug 15, 2016
Registry last updated
Feb 27, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.